News AbbVie cuts $1.9bn+ deal with IGI for trispecific antibody AbbVie has signed another deal in its effort to build an industry-leading position in multispecific antibodies for blood cancers.
News Regeneron gets long-awaited FDA okay for myeloma drug Regeneron's bid to join the crowded US market for BCMA-targeted bispecific antibodies for multiple myeloma has finally been realised.
Oncology ASCO 2025: Building a stronger future in cancer care with a ... From attending key oral sessions, clinical science symposiums and poster presentations to the simple pleasures of chatting with colleagues during coffee breaks, we left the
News J&J says two drugs are better than one in pretreated myeloma Combining Johnson & Johnson's multiple myeloma therapies Talvey and Tecvayli shows promise in a hard-to-treat form of multiple myeloma.
News NHS starts first national rollout of Blenrep for myeloma England is the first country in the world to make GSK's relaunched anti-BCMA drug Blenrep available to patients with multiple myeloma.
News ASCO 25: Sanofi hopes on-body delivery will boost Sarclisa Can a new on-body injector version of Sanofi's Sarclisa help it claim market share from J&J's rival top-selling Darzalex in multiple myeloma?
Digital Chaos & opportunity: Dr Adam Brown unpacks US health policy Dive into our video interview with Dr Adam Brown as he unpacks the chaos and opportunity shaping US health policy.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
